Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | isocitrate dehydrogenase 1 (NADP+), soluble | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.0022 | 0.0022 |
Onchocerca volvulus | 0.0999 | 0.1086 | 0.5 | |
Onchocerca volvulus | 0.0999 | 0.1086 | 0.5 | |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.0022 | 0.0022 |
Leishmania major | carnitine palmitoyltransferase-like protein | 0.1599 | 0.1766 | 0.1653 |
Echinococcus granulosus | carnitine O palmitoyltransferase 2 | 0.1599 | 0.1766 | 0.1653 |
Loa Loa (eye worm) | carnitine O-palmitoyltransferase I isoform | 0.0999 | 0.1086 | 0.1086 |
Echinococcus multilocularis | carnitine O palmitoyltransferase 2 | 0.1599 | 0.1766 | 0.1653 |
Trypanosoma cruzi | choline/carnitine O-acyltransferase, putative | 0.4627 | 0.5198 | 1 |
Echinococcus granulosus | carnitine O palmitoyltransferase 1 liver | 0.4627 | 0.5198 | 1 |
Loa Loa (eye worm) | choline/Carnitine O-acyltransferase | 0.1599 | 0.1766 | 0.1766 |
Loa Loa (eye worm) | choline O-acetyltransferase | 0.0999 | 0.1086 | 0.1086 |
Echinococcus multilocularis | carnitine O palmitoyltransferase 1, liver | 0.4627 | 0.5198 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0999 | 0.1086 | 0.1086 |
Brugia malayi | Choline O-acetyltransferase | 0.0999 | 0.1086 | 0.1086 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.0022 | 0.0022 |
Leishmania major | choline/Carnitine o-acyltransferase-like protein | 0.4627 | 0.5198 | 1 |
Schistosoma mansoni | choline o-acyltransferase | 0.0999 | 0.1086 | 1 |
Trypanosoma cruzi | carnitine O-palmitoyltransferase II, putative | 0.1599 | 0.1766 | 0.1653 |
Loa Loa (eye worm) | hypothetical protein | 0.8864 | 1 | 1 |
Onchocerca volvulus | 0.0999 | 0.1086 | 0.5 | |
Brugia malayi | Choline O-acetyltransferase | 0.0999 | 0.1086 | 0.1086 |
Brugia malayi | Choline/Carnitine o-acyltransferase family protein | 0.1599 | 0.1766 | 0.1766 |
Brugia malayi | Choline/Carnitine o-acyltransferase family protein | 0.0999 | 0.1086 | 0.1086 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.0022 | 0.0022 |
Schistosoma mansoni | choline o-acyltransferase | 0.0999 | 0.1086 | 1 |
Trypanosoma brucei | carnitine O-palmitoyltransferase II, putative | 0.1599 | 0.1766 | 1 |
Onchocerca volvulus | 0.0999 | 0.1086 | 0.5 | |
Trypanosoma cruzi | choline/carnitine O-acyltransferase, putative | 0.4627 | 0.5198 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.2311 uM | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 10 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 19.9526 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.